EA201070523A1 - Производные фталазинона - Google Patents
Производные фталазинонаInfo
- Publication number
- EA201070523A1 EA201070523A1 EA201070523A EA201070523A EA201070523A1 EA 201070523 A1 EA201070523 A1 EA 201070523A1 EA 201070523 A EA201070523 A EA 201070523A EA 201070523 A EA201070523 A EA 201070523A EA 201070523 A1 EA201070523 A1 EA 201070523A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- 6alkyl
- treatment
- substituents
- fused
- contain substituents
- Prior art date
Links
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2290008P | 2008-01-23 | 2008-01-23 | |
| US14241309P | 2009-01-05 | 2009-01-05 | |
| PCT/GB2009/000181 WO2009093032A1 (en) | 2008-01-23 | 2009-01-23 | Phthalazinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201070523A1 true EA201070523A1 (ru) | 2011-02-28 |
Family
ID=40510546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070523A EA201070523A1 (ru) | 2008-01-23 | 2009-01-23 | Производные фталазинона |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8129380B2 (enExample) |
| EP (1) | EP2231638A1 (enExample) |
| JP (1) | JP2011510056A (enExample) |
| KR (1) | KR20100116187A (enExample) |
| CN (1) | CN101925595A (enExample) |
| AR (1) | AR070221A1 (enExample) |
| AU (1) | AU2009207498A1 (enExample) |
| BR (1) | BRPI0906436A2 (enExample) |
| CA (1) | CA2708175A1 (enExample) |
| CL (1) | CL2009000133A1 (enExample) |
| CO (1) | CO6290715A2 (enExample) |
| DO (1) | DOP2010000219A (enExample) |
| EA (1) | EA201070523A1 (enExample) |
| EC (1) | ECSP10010349A (enExample) |
| IL (1) | IL206026A0 (enExample) |
| MX (1) | MX2010006364A (enExample) |
| NI (1) | NI201000120A (enExample) |
| NZ (1) | NZ585982A (enExample) |
| PE (1) | PE20091335A1 (enExample) |
| SV (1) | SV2010003625A (enExample) |
| TW (1) | TW200936577A (enExample) |
| UY (1) | UY31603A1 (enExample) |
| WO (1) | WO2009093032A1 (enExample) |
| ZA (1) | ZA201003752B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163681A (zh) * | 2005-04-21 | 2008-04-16 | 日本新药株式会社 | 2,3-二氮杂萘酮衍生物及其医药品 |
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| WO2007081030A1 (ja) * | 2006-01-16 | 2007-07-19 | Ube Industries, Ltd. | ピロロピリダジノン化合物 |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| TW201114756A (en) | 2009-07-15 | 2011-05-01 | Astrazeneca Ab | Phthalazinone compound |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102485721B (zh) * | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
| AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
| US9624197B2 (en) * | 2012-11-27 | 2017-04-18 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
| DK2938598T3 (en) | 2012-12-31 | 2017-02-13 | Cadila Healthcare Ltd | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| WO2014137883A1 (en) * | 2013-03-08 | 2014-09-12 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-ether orexin receptor antagonists |
| CA2919905C (en) * | 2013-07-31 | 2021-08-10 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CN109415345B (zh) * | 2016-06-29 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 基于哒嗪酮的广谱抗流感抑制剂 |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| CA3096127A1 (en) | 2017-04-28 | 2018-11-01 | Akribes Biomedical Gmbh | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| CA3129516A1 (en) | 2018-02-28 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents |
| SG11202011135WA (en) | 2018-05-14 | 2020-12-30 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
| CN108727338B (zh) * | 2018-07-05 | 2020-12-15 | 福建医科大学 | 一种4-哌啶酮类化合物及其制备方法与应用 |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| CN109748923A (zh) * | 2019-01-31 | 2019-05-14 | 中国药科大学 | 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途 |
| US11826430B2 (en) * | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| HUE071067T2 (hu) | 2019-07-19 | 2025-07-28 | Astrazeneca Ab | PARP1 inhibitorok |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3176219A1 (en) | 2020-04-21 | 2021-10-28 | Kunhee LEE | Crystalline forms of phthalazinone compound |
| US12060345B2 (en) | 2020-04-21 | 2024-08-13 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| CN112624981B (zh) * | 2021-03-09 | 2021-05-25 | 南京桦冠生物技术有限公司 | 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| KR20230160299A (ko) | 2021-03-23 | 2023-11-23 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체 표적화 화합물 |
| CN115197211B (zh) | 2021-04-01 | 2026-04-14 | 药捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制剂的制备方法 |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US20240343727A1 (en) * | 2021-08-17 | 2024-10-17 | InventisBio Co., Ltd. | Pyridazinone or pyridinone compounds, preparation methods and uses thereof |
| EP4514795A4 (en) * | 2022-04-28 | 2025-12-31 | Ningbo Newbay Tech Development Co Ltd | COMPOUNDS USED AS PARP1 INHIBITORS |
| CN117736150A (zh) * | 2022-09-14 | 2024-03-22 | 北京海美源医药科技有限公司 | 一种高效合成奥拉帕利关键中间体的方法和其应用 |
| WO2024146631A1 (zh) * | 2023-01-06 | 2024-07-11 | 齐鲁制药有限公司 | 一种parp7抑制剂的制备方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB721286A (en) | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
| DE2143745A1 (de) | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung |
| US3813384A (en) | 1972-01-17 | 1974-05-28 | Asta Werke Ag Chem Fab | Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof |
| FR2262513A1 (en) | 1974-03-01 | 1975-09-26 | Delalande Sa | 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity |
| JPS54156526A (en) | 1978-05-31 | 1979-12-10 | Asahi Chemical Ind | Dry picture forming material |
| US4283539A (en) | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
| JPS58164577A (ja) | 1982-03-24 | 1983-09-29 | Taiho Yakuhin Kogyo Kk | ４―ベンジル―１―（２ｈ）イソキノロン誘導体 |
| US4665181A (en) | 1984-05-17 | 1987-05-12 | Pennwalt Corporation | Anti-inflammatory phthalazinones |
| US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| ES2031813T3 (es) | 1985-11-11 | 1993-01-01 | Asta Pharma Ag | Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona. |
| GB8610018D0 (en) | 1986-04-24 | 1986-05-29 | Fujisawa Pharmaceutical Co | Phthalazine derivatives |
| DE3640641A1 (de) | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE3813531A1 (de) | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate |
| DE68920798T2 (de) | 1988-08-19 | 1995-05-18 | Warner Lambert Co | Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren. |
| EP0389995B1 (en) | 1989-03-28 | 1995-05-31 | Nisshin Flour Milling Co., Ltd. | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension |
| DD287032A5 (de) | 1989-07-28 | 1991-02-14 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen |
| GB9011833D0 (en) | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
| EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
| IL104406A0 (en) | 1992-01-17 | 1993-05-13 | Syntex Inc | Substituted 1-isoquinolone derivatives,their preparation and pharmaceutical compositions containing them |
| CZ199593A3 (en) | 1992-10-02 | 1994-04-13 | Asta Medica Ag | Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr) |
| JPH08502973A (ja) | 1992-11-02 | 1996-04-02 | メルク エンド カンパニー インコーポレーテッド | ニューロテンシンアンタゴニストとしての置換フタラジノン |
| EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| WO1996005306A2 (en) | 1994-08-12 | 1996-02-22 | Myriad Genetics, Inc. | IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE |
| PT699754E (pt) | 1994-08-12 | 2001-04-30 | Us Health | Metodo para diagnosticar uma predisposicao para cancro da mama e do ovario |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| IL120264A0 (en) | 1996-02-29 | 1997-06-10 | Pfizer | Method of reducing tissue damage associated with non-cardiac ischemia |
| CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| US5888529A (en) | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
| AU7484798A (en) | 1997-05-13 | 1998-12-08 | Octamer, Inc. | Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors |
| AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| CA2310250A1 (en) | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
| WO1999044612A1 (en) | 1998-03-02 | 1999-09-10 | Cocensys, Inc. | Substituted quinazolines and analogs and the use thereof |
| FR2776291B1 (fr) | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
| ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
| EE05006B1 (et) | 1999-01-11 | 2008-04-15 | Agouron Pharmaceuticals, Inc. | Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid |
| KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| BR0007174A (pt) | 1999-09-28 | 2001-09-04 | Basf Ag | Composto, preparação farmacêutica e uso de compostos |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US7041675B2 (en) | 2000-02-01 | 2006-05-09 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as PARP inhibitors |
| WO2001079184A1 (en) | 2000-04-18 | 2001-10-25 | Sumitomo Pharmaceuticals Company, Limited | Substituted piperazine compounds |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| WO2001087845A2 (en) | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU9578901A (en) | 2000-10-30 | 2002-05-15 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003051879A1 (en) | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AU2002360733A1 (en) | 2001-12-31 | 2003-07-24 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| US7402580B2 (en) | 2002-02-19 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2004220321B2 (en) * | 2003-03-12 | 2010-02-25 | Kudos Pharmaceuticals Ltd | Phthalazinone derivatives |
| TWI338000B (en) | 2003-12-01 | 2011-03-01 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EP1791827A1 (en) * | 2004-08-26 | 2007-06-06 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| JPWO2006137510A1 (ja) | 2005-06-24 | 2009-01-22 | 小野薬品工業株式会社 | 脳血管障害時における出血低減剤 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US7834015B2 (en) * | 2006-05-31 | 2010-11-16 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP) |
| PT2698062E (pt) * | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| AU2008299721A1 (en) * | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
-
2009
- 2009-01-21 AR ARP090100183A patent/AR070221A1/es not_active Application Discontinuation
- 2009-01-21 UY UY031603A patent/UY31603A1/es not_active Application Discontinuation
- 2009-01-22 US US12/357,957 patent/US8129380B2/en not_active Expired - Fee Related
- 2009-01-23 WO PCT/GB2009/000181 patent/WO2009093032A1/en not_active Ceased
- 2009-01-23 BR BRPI0906436-2A patent/BRPI0906436A2/pt not_active IP Right Cessation
- 2009-01-23 MX MX2010006364A patent/MX2010006364A/es not_active Application Discontinuation
- 2009-01-23 TW TW098103128A patent/TW200936577A/zh unknown
- 2009-01-23 EP EP09703506A patent/EP2231638A1/en not_active Withdrawn
- 2009-01-23 EA EA201070523A patent/EA201070523A1/ru unknown
- 2009-01-23 AU AU2009207498A patent/AU2009207498A1/en not_active Abandoned
- 2009-01-23 CN CN2009801027174A patent/CN101925595A/zh active Pending
- 2009-01-23 NZ NZ585982A patent/NZ585982A/en not_active IP Right Cessation
- 2009-01-23 JP JP2010543563A patent/JP2011510056A/ja active Pending
- 2009-01-23 CL CL2009000133A patent/CL2009000133A1/es unknown
- 2009-01-23 CA CA2708175A patent/CA2708175A1/en not_active Abandoned
- 2009-01-23 KR KR1020107017727A patent/KR20100116187A/ko not_active Withdrawn
- 2009-01-23 PE PE2009000100A patent/PE20091335A1/es not_active Application Discontinuation
-
2010
- 2010-05-26 ZA ZA2010/03752A patent/ZA201003752B/en unknown
- 2010-05-27 IL IL206026A patent/IL206026A0/en unknown
- 2010-07-16 NI NI201000120A patent/NI201000120A/es unknown
- 2010-07-16 CO CO10087223A patent/CO6290715A2/es not_active Application Discontinuation
- 2010-07-16 DO DO2010000219A patent/DOP2010000219A/es unknown
- 2010-07-16 EC EC2010010349A patent/ECSP10010349A/es unknown
- 2010-07-19 SV SV2010003625A patent/SV2010003625A/es not_active Application Discontinuation
-
2012
- 2012-01-30 US US13/361,911 patent/US20120129855A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL206026A0 (en) | 2010-11-30 |
| KR20100116187A (ko) | 2010-10-29 |
| ECSP10010349A (es) | 2010-08-31 |
| DOP2010000219A (es) | 2010-08-15 |
| SV2010003625A (es) | 2011-05-20 |
| PE20091335A1 (es) | 2009-10-04 |
| UY31603A1 (es) | 2009-08-31 |
| US8129380B2 (en) | 2012-03-06 |
| WO2009093032A1 (en) | 2009-07-30 |
| CA2708175A1 (en) | 2009-07-30 |
| CO6290715A2 (es) | 2011-06-20 |
| MX2010006364A (es) | 2010-07-05 |
| NZ585982A (en) | 2011-12-22 |
| AR070221A1 (es) | 2010-03-25 |
| TW200936577A (en) | 2009-09-01 |
| ZA201003752B (en) | 2011-03-30 |
| JP2011510056A (ja) | 2011-03-31 |
| EP2231638A1 (en) | 2010-09-29 |
| AU2009207498A1 (en) | 2009-07-30 |
| CN101925595A (zh) | 2010-12-22 |
| US20090192156A1 (en) | 2009-07-30 |
| US20120129855A1 (en) | 2012-05-24 |
| BRPI0906436A2 (pt) | 2015-07-14 |
| NI201000120A (es) | 2011-03-23 |
| CL2009000133A1 (es) | 2010-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010349A (es) | Derivados de ftalazinona | |
| JP2008535902A5 (enExample) | ||
| EA201171386A1 (ru) | ПРОИЗВОДНЫЕ ЦИКЛОПЕНТА[c]ПИРРОЛ-2-КАРБОКСИЛАТОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| ES2670674T3 (es) | Entidades químicas con actividad anticancerosa | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| CY1117113T1 (el) | Αναστολεις πρωτεασης σερινης hcv λαμβανομενοι απο μακροκυκλικη προλινη | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| RU2011108932A (ru) | Карбазольные соединения и терапевтические применения соединений | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| EA201171387A1 (ru) | Производные 7-азаспиро[3,5]нонан-7-карбоксилатов, их получение и их применение в терапии | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| EA201291073A1 (ru) | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| CO6280441A2 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| EA201291409A1 (ru) | Производные индолизина, способ их получения и их терапевтическое применение | |
| AR078540A1 (es) | Compuestos heterociclicos utiles como inhibidores de pdk1 | |
| PE20110546A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) y produccion de los mismos | |
| RU2012155118A (ru) | Способы лечения биполярного расстройства |